Epoxyeicosatrienoic acid agonist regulates human mesenchymal stem cell-derived adipocytes through activation of...

Area of Science:

• Biochemistry
• Cell Biology
• Stem Cell Research

Background:

• Human mesenchymal stem cells (MSCs) express CYP2J2, a key enzyme in epoxyeicosatrienoic acid (EET) synthesis.
• MSCs produce significant levels of EETs and dihydroxyeicosatrienoic acids (DHETs), indicating active soluble epoxide hydrolase (sEH) activity.

Purpose of the Study:

• To investigate the role of EETs in regulating adipogenesis in human MSCs.
• To elucidate the molecular mechanisms underlying EET-mediated effects on adipocyte differentiation.

Main Methods:

• MSCs were cultured and treated with EETs or an EET agonist.
• Adipogenesis was assessed by measuring lipid accumulation and the expression of key adipogenic markers (PPARγ, C/EBPα, FAS).
• The involvement of heme oxygenase-1 (HO-1), adiponectin, and AKT signaling pathways was examined using specific inhibitors (SnMP, LY2940002).

Main Results:

• EETs significantly reduced MSC-derived adipocyte differentiation in a dose-dependent manner.
• An EET agonist increased healthy small adipocytes, decreased fatty acid synthase (FAS) and lipid accumulation, and upregulated HO-1 and adiponectin levels.
• EET-induced inhibition of adipogenesis was reversed by inhibiting HO activity or AKT, confirming the involvement of the HO-1-adiponectin-AKT axis.

Conclusions:

• EETs play a crucial role in inhibiting MSC adipogenesis by upregulating the HO-1-adiponectin-AKT signaling pathway.
• EETs regulate adipocyte differentiation by inhibiting key transcription factors (PPARγ, C/EBPα) and FAS.
• These findings suggest that EET agonists hold therapeutic potential for metabolic disorders like dyslipidemia, diabetes, and the metabolic syndrome.